Amazon (AMZN) Pharmacy expands access to Eli Lilly's Zepbound Kwikpen for weight loss; offered at USD 299/mth for 2.5mg dosage
Context
Amazon’s expansion into the pharmacy space with Eli Lilly's Zepbound Kwikpen marks a significant move in the competitive weight loss market. At a monthly price point of USD 299, this could attract a considerable customer base while diversifying Amazon’s healthcare offerings, potentially affecting equities in both the retail and pharmaceutical sectors. Watch for industry peers' reactions and any shifts in market sentiment regarding online pharmacy services.
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard#UNITED STATES#USD#EUR#JAPAN#JPY#UNITED KINGDOM#GBP#EUROPE#AMAZON.COM INC#AMZN.US#ELI LILLY & CO#FOREX#EQUITIES#METALS#EU SESSION#BROADLINE RETAIL#METALS & MINING#BROADLINE RETAIL (GROUP)#CONSUMER DISCRETIONARY DISTRIBUTION & RETAIL#S&P 500 INDEX#NASDAQ 100 INDEX#AMZN#DXY#US EQUITIES